425: Alumis to Acquire ACELYRIN in Merger Deal, Creating Late-Stage Clinical Biopharma Powerhouse

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement to create a leading immunology and inflammation (I&I) company with a diversified pipeline and extended cash runway.

Summary

• Alumis Inc. and ACELYRIN, Inc. have entered into a merger agreement, with Alumis acquiring ACELYRIN.
• The merger aims to create a late-stage clinical biopharmaceutical company focused on immune-mediated diseases.
• The combined company will have a diversified pipeline, including ESK-001, A-005, and lonigutamab.
• Topline data from the Phase 3 ONWARD trials for ESK-001 in moderate-to-severe plaque psoriasis is now expected in 1Q 2026.
• Topline data from the Phase 2b LUMUS trial in systemic lupus erythematosus is on track for readout in 2026.
• A Phase 2 clinical trial for A-005 in multiple sclerosis is expected to initiate in 2025, with topline data in 2026.
• The combined company will have pro forma cash of approximately $737 million as of December 31, 2024, providing a cash runway into 2027.
• ACELYRIN stockholders are expected to own 45% of the combined company.
• The merger is expected to be 41%-48% value accretive to ACELYRIN stockholders.
• The ACELYRIN board determined that a transaction that supported the continued development of lonigutamab represented the best opportunity for long-term value creation for ACELYRIN stockholders.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential for value creation and a strong pipeline. However, it also acknowledges the inherent risks and uncertainties associated with the transaction and drug development, resulting in a moderately positive sentiment.

Positives

• The merger creates a company with a late-stage, diversified pipeline targeting immune-mediated diseases.
• The combined company has a strong cash position, providing runway into 2027.
• The merger is expected to be value accretive to ACELYRIN stockholders.
• The transaction supports the continued development of lonigutamab for thyroid eye disease.
• The combined company will benefit from a world-class leadership team with a proven track record.

Negatives

• The merger is subject to customary closing conditions, including stockholder approvals, and may not be completed in a timely manner or at all.
• The announcement and pendency of the merger could affect Alumis' and ACELYRIN's ability to attract and retain key personnel.
• Integration of the two companies may not occur as anticipated, and the combined company may not achieve expected growth prospects.
• There are risks associated with the development, commercialization, and regulatory approval of the combined company's product candidates.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals of the proposed transaction, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the proposed transaction may negatively impact Alumis' and ACELYRIN's ability to attract and retain key personnel.
• The proposed transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the proposed transaction could arise.
• Alumis or ACELYRIN may be adversely affected by economic, business, and/or competitive factors.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• There are risks related to the development, commercialization, and regulatory approval of product candidates.

Future Outlook

The combined company aims to innovate, develop, and commercialize transformative therapies for immune-mediated diseases, with multiple upcoming milestones expected and a cash runway into 2027.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to enhance pipeline diversity, reduce risk, and leverage synergies in drug development and commercialization, particularly in the competitive immunology and inflammation space.

Comparison to Industry Standards

• The document references Tepezza, a treatment for thyroid eye disease, suggesting that Alumis' Chief Commercial Officer has experience in a similar market.
• The document mentions a $60Bn+ market potential across immune-mediated diseases, suggesting that the combined company will be a significant player in the industry.

Stakeholder Impact

• ACELYRIN stockholders are expected to benefit from the value accretion and participation in the combined company's upside.
• Employees of both companies may experience changes related to the integration of the businesses.
• Patients may benefit from the development of new therapies for immune-mediated diseases.

Next Steps

• Alumis intends to file a registration statement with the SEC, including a joint proxy statement/prospectus.
• Stockholder approvals from both Alumis and ACELYRIN will be required.
• The companies will work to satisfy the other conditions to the consummation of the transaction.
• Post transaction close, the combined company expects to evaluate lonigutamab's potential in TED with approximately $25-50M of committed capital.

Key Dates